Dimethyltryptamine and the Recursive Reorganization of Consciousness

N,N-dimethyltryptamine (DMT) is a rapidly acting serotonergic psychedelic capable of reorganizing perception, bodily selfhood, spatial enclosure, agency attribution, and experienced reality over an unusually compressed timescale. Controlled human studies report concentration-dependent pharmacodynamic effects, pronounced suppression of alpha-band activity, increased electrophysiological signal diversity, greater global functional connectivity, reduced integrity and segregation of established functional networks, compression of the principal cortical gradient, and modeled reductions in the control energy required for transitions among measured brain states. These findings establish important components of the acute response, but they do not yet provide a unified causal account of how molecular perturbation develops into an immersive and apparently autonomous experiential world, why related structural motifs recur across reports, why pharmacologically comparable sessions may diverge, or why some participants report an inability to regain a previously accessible state.

This monograph develops a multilevel causal architecture linking pharmacokinetics, receptor-field activation, cellular gain modulation, whole-brain dynamics, embodied physiology, phenomenological organization, memory, environment, recovery, and post-session updating. The architecture distinguishes departure from ordinary waking organization from approach toward a candidate recurrent DMT-state organization. It introduces independently constructed waking and candidate DMT-state reference manifolds, frozen predictive and descriptive embeddings, bounded reference-fit scores, and an altered-over-waking reference-dominance margin. Breakthrough is defined provisionally as sustained altered-reference dominance above a preregistered threshold for a minimum dwell duration, rather than as a synonym for dose, visual intensity, signal diversity, ego dissolution, or peak subjective magnitude.

Worldhood, perceived agency, hyperreality, bodily self-location, self-model destabilization, grounding, recurrence failure, and multidomain recovery are modeled as distinguishable but interacting constructs. Repeated sessions are treated as potentially path-dependent because each episode may modify the memories, expectations, interpretations, regulatory responses, and initial conditions presented to the next exposure. Participant-reported “lockout” is first typed according to pharmacological comparability and reported target-state failure. Records typed as CANDIDATE are then decomposed into waking-reference persistence, altered fragmentation, path divergence, recognition failure, selective preservation of embodiment, protective re-stabilization, report reconstruction, mixed mechanism, and subtype-non-evaluable cases.

Within the GCD–UMCP architecture, the introduced manifold, phenomenological, embodiment, recurrence-failure, and recovery quantities remain Tier-2 diagnostics. They do not redefine the reserved Tier-1 quantities {ω,F,S,C,τR,κ,IC}\{\omega,F,S,C,\tau_R,\kappa,IC\}{ω,F,S,C,τR,κ,IC}, and they do not independently establish canonical collapse, integrity gain, admissible return, or welded continuity.

The analysis separates direct controlled evidence, convergent human evidence, structured phenomenology, constrained computational inference, GCD–UMCP modeling, novel hypothesis, and ontological claim. Proposed mechanisms involving regulatory memory, targeted desire, observer preservation, selective embodiment, agentive boundary rendering, recurrence failure, and asynchronous recovery are presented as falsifiable hypotheses rather than established clinical facts. The framework remains agnostic regarding the mind-independent existence of perceived entities, environments, places, or dimensions.

Ten prospective predictions, six comparative baseline classes, three-valued local prediction stances, explicit contraction conditions, leakage controls, preserved result records, and a repeated-session multimodal validation design are specified. The resulting account treats DMT as a short-duration perturbational probe of how a living nervous system constructs a self, stabilizes a world, attributes agency and reality, redistributes experiential authority among competing organizations, undergoes multidomain recovery, and, where admissible re-entry is demonstrated under an unchanged contract, returns toward waking organization with a changed causal history.